

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GLAXOSMITHKLINE PLC			2. Issuer Name and Ticker or Trading Symbol CVRx, Inc. [CVRX]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/02/2021			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
980 GREAT WEST ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) BRENTFORD MIDDLESEX X0 TW8 9GS								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/02/2021		C		1,505	A	(2)	33,316	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		C		12,979	A	(2)	46,295	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		C		14,917	A	(2)	61,212	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		C		8,380	A	(2)	69,592	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		C		27,345	A	(2)	96,937	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		C		635,646	A	(3)	732,583	I	See Footnote ⁽⁴⁾
Common Stock	07/02/2021		P ⁽¹⁾		275,000	A	\$18	1,007,583	I	See Footnote ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B-2 Preferred Stock	(2)	07/02/2021		C		59,527		(2)	(2)	Common Stock	1,505	\$0	0	I	See Footnote ⁽⁴⁾
Series C-2 Preferred Stock	(2)	07/02/2021		C		513,312		(2)	(2)	Common Stock	12,979	\$0	0	I	See Footnote ⁽⁴⁾
Series D-2 Preferred Stock	(2)	07/02/2021		C		589,939		(2)	(2)	Common Stock	14,917	\$0	0	I	See Footnote ⁽⁴⁾
Series E-2 Preferred Stock	(2)	07/02/2021		C		331,399		(2)	(2)	Common Stock	8,380	\$0	0	I	See Footnote ⁽⁴⁾
Series F-2 Preferred Stock	(2)	07/02/2021		C		1,081,434		(2)	(2)	Common Stock	27,345	\$0	0	I	See Footnote ⁽⁴⁾
Series G Preferred Stock	(3)	07/02/2021		C		10,055,408		(3)	(3)	Common Stock	635,646	\$0	0	I	See Footnote ⁽⁴⁾

Explanation of Responses:

- Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
- The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
- The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.

/s/ Victoria Whyte

07/06/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.